text_1: A number of studies have identified unbiased strategies to treat KRAS mutant cancers through RNA interference screens, including inhibition of TAK1, STK33, TBK1, WT1, GATA2, and BCL-XL/MEK.
text_2: This would also permit the use of inhibitors that target a single normal protein on which in particular the tumor cells depend as the result of a mutation in a defined pathway. 